
usd pm et
summari contract clinic research organ provid health care data
nm price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
risk assess account benefit
diversifi servic signific earn come
health care technolog analyt well
contract research servic drug develop
expect two industri experi long-term
demand growth advanc medicin prolifer
around globe benefit balanc view
signific competit face major
advers impact stem withdraw delay
larg drug develop project
may ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
star recommend
recent chang sell
hold highlight section stock
report updat accordingli
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
maintain target
price ep estim
downgrad opinion howev
think futur growth justifi
current premium valuat increas
invest capit last three
year acquisit intend improv
competit posit think
posit improv howev
estim organ sale growth
yoy materi lag revenu growth
broader health care sector
believ technolog analyt segment
lose market share organ growth
rate materi lag competitor
optuminsight yoy also expect
grow total sale around
materi lag growth expect
peer like iclr given forecast
below-averag growth current
trade highest forward price-to-earnings
industri expect share under-perform
broader market year ahead /colin
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview quintilesim hold inc form octob merger
quintil transnat lead contract research organ im health lead provid
prescript electron health record data combin compani lead integr
inform technolog healthcar servic provid novemb quintilesim chang name
iqvia
quintil provid biopharmaceut develop servic commerci outsourc servic
conduct busi approxim countri quintil offer servic two segment
product develop integr healthcar servic product develop provid servic
expertis enabl biopharmaceut compani outsourc clinic develop process
first-in-man clinic trial post-launch monitor product develop compris clinic
solut servic consult clinic solut servic provid servic necessari develop
biopharmaceut product includ project manag clinic monitor function
conduct multi-sit clinic trial gener phase ii-iv clinic trial support servic
improv clinic trial decision-mak data manag strateg plan design servic
improv decis perform consult provid strategi manag consult
servic base deep life scienc expertis advanc analyt well regulatori complianc
consult servic clinic solut servic enabl conduct coordin multi-sit
clinic trial gener phase ii-iv servic offer includ protocol design feasibl
oper plan site start patient recruit project manag monitor
investig site data patient visit
im oper inform technolog servic compani provid client health care
industri solut measur improv perform world-wide compani
collect health care inform span sale prescript promot data medic claim
electron medic record social media compani data set contain approxim petabyt
data approxim million longitudin anonym patient record record link
time anonym individu across health care set compani presenc
compani serv key health care organ decis maker world-wide span breadth
life scienc compani includ pharmaceut biotechnolog consum health medic devic
manufactur well distributor provid payer govern agenc policymak research
financi commun juli compani oper three busi segment
contract sale medic solut formerli integr engag servic
compani princip inform offer compris nation inform offer approxim
countri provid consist country-level perform metric relat sale pharmaceut
product prescrib trend medic treatment promot activ across multipl channel
includ retail hospit mail order client use product measur rel perform
assess market opportun determin brand compani strategi understand market dynam
product avail rang frequenc weekli annual deliv variou
format includ on-line host pc mobil platform
compani sub-nat offer compris servic approxim countri provid
consist measur sale prescrib activ region zip code individu prescrib
level product use extens major pharmaceut sale organ within
countri depend servic set goal determin resourc measur perform
calcul compens compani onekey refer databas track approxim million
health care profession countri provid view health care practition critic
commerci success market sale initi
compani also provid rang cloud-bas applic associ implement servic
softwar servic saa solut support rang commerci regulatori process includ
compens territori align roster manag call plan complianc report master
data manag solut use health care compani manag optim execut
commerci strategi orchestr manner meet regulatori oblig
competit within technolog analyt solut compani face numer competitor
includ larg corpor certain govern agenc corpor competitor includ cogniz
technolog covanc optuminsight parexel intern among other within
unit competitor includ tradit contract research organ icon plc covanc
parexel syneo pharmaceut product develop
financi trend januari adopt revenu recognit standard
new standard recogn revenu unit percentag complet basi
standard requir servic revenu reimburs expens revenu treat consist
present one line incom statement report revenu re-cast
revenu would first full year combin oper
former quintil transnat im health adjust ep
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc march technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
lst sub-industri
next month think among
fastest-grow sub-industri within health
care sector driver earn growth
sub-industri next year
view strong growth public fund
health care research increas
spend biopharmaceut compani
budget nation institut
nih grew rapidli last three year
materi increas fund academ
govern lab turn drive sale
growth lst compani gener
materi portion revenu lab
fy nih budget grew
fy
budget increas aid lst
sub-industri sale growth
forecast
expect anoth materi nih budget
increas fy support robust
demand sub-industri product
year ahead well
addit public-fund health care
research expect larg increas privat
biopharmaceut spend drive sale
growth life scienc tool servic
sub-industri month end septemb
estim spend
increas year-over-year
spend biotech
depart research tool product
well contract research servic
 growth continu year ahead
translat continu solid sale growth
lst sub-industri
care research type prolifer
around world particularli china
emerg market turn
drive strong intern sale growth
establish life scienc tool servic
compani china particular
view howev tailwind may moder
china face slowdown econom
growth use five largest compani
lst sub-industri proxi estim
averag growth sub-industri
china-deriv sale slow
year-over-year
long-term though think china
major emerg market nation like india
need continu rapidli increas health care
expenditur parallel grow
middl class turn like continu
support strong sale growth lst
sub-industri see happen despit
potenti neg impact
import/export tariff limit
large-scal supplier option
state-of-the-art lst product outsid
compani notabl except
switzerland-bas roch
 life
rise
 life
drop
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
keep target price line peer
ep estim ep vs ahead
estim adopt account standard recogn
revenu percentag complet basi requir reimburs expens
servic revenu consist present one line incom
statement sale includ fx benefit rose commerci
solut research develop solut integr
engag iqv smallest unit net new busi research
develop unit last month rose quarterli
basi net new busi win rose book-to-bil backlog
march modest encourag net
new busi sign note iqv leverag remain high net debt/ebitda
/jeffrey loo cfa
et cfra keep hold opinion share ia hold
rais target line peer
ep estim set ep
vs ahead estim pro-forma sale rose
commerci solut research develop solut
integr engag servic fell guid sale
re-cast sale adopt
revenu recogn percentag complet basi
reimburs expens treat consist servic revenu /jeffrey
analyst research note compani news
pm et cfra lower recommend share
sell hold maintain target price
ep estim downgrad opinion howev think
futur growth justifi current premium valuat increas
invest capit last three year acquisit
intend improv competit posit think posit
improv howev estim organ sale growth yoy
materi lag revenu growth broader health care sector
believ technolog analyt segment lose market share
organ growth rate materi lag competitor optuminsight
yoy also expect grow total sale around materi
lag growth expect peer like iclr given forecast
below-averag growth current trade highest forward
price-to-earnings industri expect share under-perform broader market
pm et cfra maintain hold recommend share
inc rais target
ep estim -- histor forward price-to-earnings averag due
strong growth outlook segment ep vs
beat consensu keep ep estim
revenu grew yoy led growth organ
technolog analyt sale growth organ
solut growth strong note
organ rate technolog analyt materi lag competitor
like optuminsight cogniz healthcar grew sale yoy
respect view indic segment may lose market
share execut well oper side lower sg yoy
materi improv adjust pre-tax margin
expect drive ep growth think
share alreadi near fair valu /colin scarola
inc hold buy drop target
ep estim premium histor averag due recent
custom win analyt ep vs
ahead estim rais ep estim
initi revenu growth slow
 segment led slowdown sale growth yoy
despit strong book-to-bil ratio preced quarter
 analyt segment total growth yoy strong
disappoint organ growth rate especi compar
peer optuminsight cogniz healthcar grow materi faster
despit top-lin growth estim earn tax amort
ebta fell yoy higher sg interest restructur
integr expens hurt margin less comfort high
leverag given slow revenu growth lower ebta /colin scarola
et cfra rais recommend share iqvia hold
inc buy hold rais target
line peer forward ep estim
ep vs ahead estim rais
ep estim ep estim
sale rose technolog analyt solut formerli commerci
solut research develop solut rose
servic fell contract sale smallest unit account
sale within latest net new
busi win year-ago period quarterli
basi book-to-bil robust see invest
technolog innov enabl compani win new busi client
ad new custom
encourag new busi win client add believ
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
